Flagship Biosciences

Flagship Bio is using ACD's RNAscope and customizing and optimizing the technology for use in CLIA clinical trials with "several large pharmaceutical clients."

NEW YORK (GenomeWeb) – Danaher's Leica Biosystems will use Flagship Biosciences' custom algorithms to develop companion diagnostics on the Aperio ePathology imaging platform, Flagship said today.
Financial and other terms of the deal were not disclosed.

Flagship Biosciences will use Affymetrix Quantigene ViewRNA assays as part of a new tissue-based RNA in situ hybridization analysis service.

NEW YORK (GenomeWeb News) – Companion diagnostics and biomarker development company Flagship Biosciences announced late on Monday its purchase of immunohistochemistry and immunofluorescence firm IHCtech for an undisclosed amount.

The deal combines TGen's molecular analysis tools with Flagship's expertise in high-throughput immunohistochemistry to support preclinical drug development and human clinical trials.

The deal combines Expression Pathology's mass spec-based assays for FFPE tissue with Flagship's pathology expertise, allowing the partners to identify tissue features or sub-anatomic organelles of research interest and then extract and prep them for proteomic analysis.

The partnership will enable tissue translational biomarker development, validation, and application to support new drug development, according to Flagship Biosciences.

Epigenetics company PrognosDx and digital pathology firm Flagship will offer laboratory-based testing services initially to therapeutic oncology programs at pharmaceutical firms.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.